Which has better valuation & earnings, ZLAB or NGNE?

Neurogene has lower revenue, but higher earnings than Zai Lab. Zai Lab is trading at a lower price-to-earnings ratio than Neurogene, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Zai Lab $460.16M 6.34 -$175.54M -$1.71 N/A Neurogene $930K 852.90 -$90.35M -$5.03 N/A

Is ZLAB or NGNE more profitable?

Neurogene has a net margin of 0.00% compared to Zai Lab's net margin of -41.86%. Zai Lab's return on equity of -27.43% beat Neurogene's return on equity. Company Net Margins Return on Equity Return on Assets Zai Lab -41.86% -27.43% -16.72% Neurogene N/A -45.10% -41.00%

Does the media prefer ZLAB or NGNE?

In the previous week, Zai Lab had 1 more articles in the media than Neurogene. MarketBeat recorded 2 mentions for Zai Lab and 1 mentions for Neurogene. Zai Lab's average media sentiment score of 0.74 beat Neurogene's score of 0.00 indicating that Zai Lab is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Zai Lab 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Neurogene 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media refer more to NRIX or NGNE?

In the previous week, Nurix Therapeutics had 5 more articles in the media than Neurogene. MarketBeat recorded 6 mentions for Nurix Therapeutics and 1 mentions for Neurogene. Nurix Therapeutics' average media sentiment score of 1.11 beat Neurogene's score of 0.00 indicating that Nurix Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Nurix Therapeutics 3 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Neurogene 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media favor NGNE or BEAM?

In the previous week, Beam Therapeutics had 3 more articles in the media than Neurogene. MarketBeat recorded 4 mentions for Beam Therapeutics and 1 mentions for Neurogene. Beam Therapeutics' average media sentiment score of 1.16 beat Neurogene's score of 0.00 indicating that Beam Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Neurogene 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Beam Therapeutics 3 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor NGNE or VRDN?

In the previous week, Viridian Therapeutics had 10 more articles in the media than Neurogene. MarketBeat recorded 11 mentions for Viridian Therapeutics and 1 mentions for Neurogene. Viridian Therapeutics' average media sentiment score of 1.19 beat Neurogene's score of 0.00 indicating that Viridian Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Neurogene 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Viridian Therapeutics 9 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Is SLS or NGNE more profitable?

SELLAS Life Sciences Group's return on equity of -35.91% beat Neurogene's return on equity. Company Net Margins Return on Equity Return on Assets SELLAS Life Sciences Group N/A -35.91% -33.34% Neurogene N/A -45.10% -41.00%

Does the media refer more to SLS or NGNE?

In the previous week, SELLAS Life Sciences Group had 10 more articles in the media than Neurogene. MarketBeat recorded 11 mentions for SELLAS Life Sciences Group and 1 mentions for Neurogene. SELLAS Life Sciences Group's average media sentiment score of 0.60 beat Neurogene's score of 0.00 indicating that SELLAS Life Sciences Group is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment SELLAS Life Sciences Group 5 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive Neurogene 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Neurogene (NGNE) Competitors

$39.64 +1.01 (+2.61%)

Closing price 04:00 PM Eastern

Extended Trading

$39.66 +0.02 (+0.05%)

As of 04:31 PM Eastern

Compare

NGNE vs. ZLAB, NRIX, BEAM, VRDN, and SLS

Should you buy Neurogene stock or one of its competitors? Neurogene's main competitors and comparable companies include Zai Lab (ZLAB), Nurix Therapeutics (NRIX), Beam Therapeutics (BEAM), Viridian Therapeutics (VRDN), and SELLAS Life Sciences Group (SLS). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Neurogene compare to Zai Lab?

Zai Lab (NASDAQ:ZLAB) and Neurogene (NASDAQ:NGNE) are both healthcare companies, but which is the better investment? We will compare the two companies based on the strength of their dividends, media sentiment, risk, institutional ownership, analyst recommendations, earnings, valuation and profitability.

In the previous week, Zai Lab had 1 more articles in the media than Neurogene. MarketBeat recorded 2 mentions for Zai Lab and 1 mentions for Neurogene. Zai Lab's average media sentiment score of 0.74 beat Neurogene's score of 0.00 indicating that Zai Lab is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Zai Lab	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Neurogene	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Zai Lab currently has a consensus target price of $40.20, indicating a potential upside of 56.79%. Neurogene has a consensus target price of $83.67, indicating a potential upside of 111.07%. Given Neurogene's stronger consensus rating and higher probable upside, analysts plainly believe Neurogene is more favorable than Zai Lab.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Zai Lab	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.71
Neurogene	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.83

Neurogene has lower revenue, but higher earnings than Zai Lab. Zai Lab is trading at a lower price-to-earnings ratio than Neurogene, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Zai Lab	$460.16M	6.34	-$175.54M	-$1.71	N/A
Neurogene	$930K	852.90	-$90.35M	-$5.03	N/A

Zai Lab has a beta of 0.78, meaning that its share price is 22% less volatile than the broader market. Comparatively, Neurogene has a beta of 1.7, meaning that its share price is 70% more volatile than the broader market.

41.7% of Zai Lab shares are held by institutional investors. Comparatively, 52.4% of Neurogene shares are held by institutional investors. 4.9% of Zai Lab shares are held by company insiders. Comparatively, 11.7% of Neurogene shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Neurogene has a net margin of 0.00% compared to Zai Lab's net margin of -41.86%. Zai Lab's return on equity of -27.43% beat Neurogene's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Zai Lab	-41.86%	-27.43%	-16.72%
Neurogene	N/A	-45.10%	-41.00%

Summary

Neurogene beats Zai Lab on 9 of the 15 factors compared between the two stocks.

How does Neurogene compare to Nurix Therapeutics?

Nurix Therapeutics (NASDAQ:NRIX) and Neurogene (NASDAQ:NGNE) are both healthcare companies, but which is the better business? We will contrast the two businesses based on the strength of their earnings, profitability, risk, institutional ownership, valuation, dividends, analyst recommendations and media sentiment.

Neurogene has a net margin of 0.00% compared to Nurix Therapeutics' net margin of -928.44%. Neurogene's return on equity of -45.10% beat Nurix Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Nurix Therapeutics	-928.44%	-76.09%	-57.31%
Neurogene	N/A	-45.10%	-41.00%

Neurogene has lower revenue, but higher earnings than Nurix Therapeutics. Neurogene is trading at a lower price-to-earnings ratio than Nurix Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Nurix Therapeutics	$36.77M	74.15	-$264.46M	-$3.45	N/A
Neurogene	$930K	852.90	-$90.35M	-$5.03	N/A

Nurix Therapeutics has a beta of 1.79, indicating that its share price is 79% more volatile than the broader market. Comparatively, Neurogene has a beta of 1.7, indicating that its share price is 70% more volatile than the broader market.

Nurix Therapeutics currently has a consensus target price of $34.21, suggesting a potential upside of 30.24%. Neurogene has a consensus target price of $83.67, suggesting a potential upside of 111.07%. Given Neurogene's stronger consensus rating and higher probable upside, analysts clearly believe Neurogene is more favorable than Nurix Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Nurix Therapeutics	1 Sell rating(s)	1 Hold rating(s)	13 Buy rating(s)	0 Strong Buy rating(s)	2.80
Neurogene	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.83

In the previous week, Nurix Therapeutics had 5 more articles in the media than Neurogene. MarketBeat recorded 6 mentions for Nurix Therapeutics and 1 mentions for Neurogene. Nurix Therapeutics' average media sentiment score of 1.11 beat Neurogene's score of 0.00 indicating that Nurix Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Nurix Therapeutics	3 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Neurogene	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

52.4% of Neurogene shares are owned by institutional investors. 6.7% of Nurix Therapeutics shares are owned by insiders. Comparatively, 11.7% of Neurogene shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Summary

Neurogene beats Nurix Therapeutics on 10 of the 17 factors compared between the two stocks.

How does Neurogene compare to Beam Therapeutics?

Neurogene (NASDAQ:NGNE) and Beam Therapeutics (NASDAQ:BEAM) are both healthcare companies, but which is the superior stock? We will contrast the two businesses based on the strength of their institutional ownership, valuation, analyst recommendations, media sentiment, earnings, profitability, risk and dividends.

Neurogene has a net margin of 0.00% compared to Beam Therapeutics' net margin of -54.75%. Beam Therapeutics' return on equity of -30.71% beat Neurogene's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Neurogene	N/A	-45.10%	-41.00%
Beam Therapeutics	-54.75%	-30.71%	-24.07%

Neurogene currently has a consensus price target of $83.67, indicating a potential upside of 111.07%. Beam Therapeutics has a consensus price target of $49.00, indicating a potential upside of 72.96%. Given Neurogene's stronger consensus rating and higher probable upside, research analysts plainly believe Neurogene is more favorable than Beam Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Neurogene	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.83
Beam Therapeutics	1 Sell rating(s)	2 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.69

Beam Therapeutics has higher revenue and earnings than Neurogene. Beam Therapeutics is trading at a lower price-to-earnings ratio than Neurogene, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Neurogene	$930K	852.90	-$90.35M	-$5.03	N/A
Beam Therapeutics	$156.04M	18.75	-$79.99M	-$0.86	N/A

In the previous week, Beam Therapeutics had 3 more articles in the media than Neurogene. MarketBeat recorded 4 mentions for Beam Therapeutics and 1 mentions for Neurogene. Beam Therapeutics' average media sentiment score of 1.16 beat Neurogene's score of 0.00 indicating that Beam Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Neurogene	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Beam Therapeutics	3 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

52.4% of Neurogene shares are owned by institutional investors. Comparatively, 99.7% of Beam Therapeutics shares are owned by institutional investors. 11.7% of Neurogene shares are owned by insiders. Comparatively, 3.8% of Beam Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Neurogene has a beta of 1.7, indicating that its share price is 70% more volatile than the broader market. Comparatively, Beam Therapeutics has a beta of 2.23, indicating that its share price is 123% more volatile than the broader market.

Summary

Beam Therapeutics beats Neurogene on 10 of the 17 factors compared between the two stocks.

How does Neurogene compare to Viridian Therapeutics?

Neurogene (NASDAQ:NGNE) and Viridian Therapeutics (NASDAQ:VRDN) are both healthcare companies, but which is the superior stock? We will contrast the two companies based on the strength of their profitability, dividends, institutional ownership, risk, earnings, valuation, media sentiment and analyst recommendations.

52.4% of Neurogene shares are held by institutional investors. 11.7% of Neurogene shares are held by insiders. Comparatively, 2.4% of Viridian Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Neurogene currently has a consensus price target of $83.67, suggesting a potential upside of 111.07%. Viridian Therapeutics has a consensus price target of $38.93, suggesting a potential upside of 62.07%. Given Neurogene's higher probable upside, analysts plainly believe Neurogene is more favorable than Viridian Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Neurogene	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.83
Viridian Therapeutics	1 Sell rating(s)	0 Hold rating(s)	13 Buy rating(s)	0 Strong Buy rating(s)	2.86

In the previous week, Viridian Therapeutics had 10 more articles in the media than Neurogene. MarketBeat recorded 11 mentions for Viridian Therapeutics and 1 mentions for Neurogene. Viridian Therapeutics' average media sentiment score of 1.19 beat Neurogene's score of 0.00 indicating that Viridian Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Neurogene	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Viridian Therapeutics	9 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Neurogene has a net margin of 0.00% compared to Viridian Therapeutics' net margin of -505.86%. Neurogene's return on equity of -45.10% beat Viridian Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Neurogene	N/A	-45.10%	-41.00%
Viridian Therapeutics	-505.86%	-72.97%	-42.80%

Neurogene has higher earnings, but lower revenue than Viridian Therapeutics. Neurogene is trading at a lower price-to-earnings ratio than Viridian Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Neurogene	$930K	852.90	-$90.35M	-$5.03	N/A
Viridian Therapeutics	$71.13M	38.26	-$342.60M	-$3.37	N/A

Neurogene has a beta of 1.7, indicating that its stock price is 70% more volatile than the broader market. Comparatively, Viridian Therapeutics has a beta of 0.91, indicating that its stock price is 9% less volatile than the broader market.

Summary

Neurogene beats Viridian Therapeutics on 10 of the 17 factors compared between the two stocks.

How does Neurogene compare to SELLAS Life Sciences Group?

SELLAS Life Sciences Group (NASDAQ:SLS) and Neurogene (NASDAQ:NGNE) are both healthcare companies, but which is the better business? We will compare the two businesses based on the strength of their dividends, media sentiment, profitability, valuation, analyst recommendations, institutional ownership, earnings and risk.

SELLAS Life Sciences Group has a beta of 2.48, indicating that its share price is 148% more volatile than the broader market. Comparatively, Neurogene has a beta of 1.7, indicating that its share price is 70% more volatile than the broader market.

17.4% of SELLAS Life Sciences Group shares are held by institutional investors. Comparatively, 52.4% of Neurogene shares are held by institutional investors. 1.3% of SELLAS Life Sciences Group shares are held by insiders. Comparatively, 11.7% of Neurogene shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

SELLAS Life Sciences Group currently has a consensus target price of $10.00, suggesting a potential downside of 30.17%. Neurogene has a consensus target price of $83.67, suggesting a potential upside of 111.07%. Given Neurogene's stronger consensus rating and higher probable upside, analysts clearly believe Neurogene is more favorable than SELLAS Life Sciences Group.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
SELLAS Life Sciences Group	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33
Neurogene	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.83

In the previous week, SELLAS Life Sciences Group had 10 more articles in the media than Neurogene. MarketBeat recorded 11 mentions for SELLAS Life Sciences Group and 1 mentions for Neurogene. SELLAS Life Sciences Group's average media sentiment score of 0.60 beat Neurogene's score of 0.00 indicating that SELLAS Life Sciences Group is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
SELLAS Life Sciences Group	5 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive
Neurogene	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

SELLAS Life Sciences Group's return on equity of -35.91% beat Neurogene's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
SELLAS Life Sciences Group	N/A	-35.91%	-33.34%
Neurogene	N/A	-45.10%	-41.00%

SELLAS Life Sciences Group has higher earnings, but lower revenue than Neurogene. SELLAS Life Sciences Group is trading at a lower price-to-earnings ratio than Neurogene, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
SELLAS Life Sciences Group	N/A	N/A	-$26.86M	-$0.21	N/A
Neurogene	$930K	852.90	-$90.35M	-$5.03	N/A

Summary

Neurogene beats SELLAS Life Sciences Group on 8 of the 15 factors compared between the two stocks.

Get Neurogene News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding NGNE and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

NGNE vs. The Competition

Export

Metric	Neurogene	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$793.20M	$3.99B	$7.29B	$12.71B
Dividend Yield	N/A	3.64%	2.54%	10.79%
P/E Ratio	-7.88	11.78	271.39	24.10
Price / Sales	852.90	1,299.82	604.58	77.05
Price / Cash	N/A	44.94	29.03	36.90
Price / Book	2.32	17.27	11.18	6.40
Net Income	-$90.35M	-$22.72M	$3.46B	$348.28M
7 Day Performance	8.07%	2.91%	1.98%	0.92%
1 Month Performance	13.58%	9.75%	7.32%	5.10%
1 Year Performance	98.30%	54.82%	24.76%	16.16%

Neurogene Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
NGNE Neurogene	1.7468 of 5 stars	$39.64 +2.6%	$83.67 +111.1%	+93.2%	$793.20M	$930K	N/A	90	High Trading Volume
ZLAB Zai Lab	2.399 of 5 stars	$25.55 -0.4%	$40.20 +57.4%	-25.8%	$2.90B	$460.16M	N/A	1,784	Gap Down
NRIX Nurix Therapeutics	3.1276 of 5 stars	$26.73 -1.6%	$34.21 +28.0%	+163.5%	$2.78B	$36.77M	N/A	300	Positive News
BEAM Beam Therapeutics	2.1679 of 5 stars	$26.36 -2.7%	$49.00 +85.9%	+78.8%	$2.72B	$156.04M	N/A	510	Positive News
VRDN Viridian Therapeutics	2.7481 of 5 stars	$23.43 +1.5%	$38.93 +66.2%	+26.3%	$2.65B	$71.13M	N/A	50	Positive News

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:NGNE) was last updated on 8/24/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Neurogene (NGNE) Competitors

NGNE vs. ZLAB, NRIX, BEAM, VRDN, and SLS

How does Neurogene compare to Zai Lab?

Summary

How does Neurogene compare to Nurix Therapeutics?

Summary

How does Neurogene compare to Beam Therapeutics?

Summary

How does Neurogene compare to Viridian Therapeutics?

Summary

How does Neurogene compare to SELLAS Life Sciences Group?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

NGNE vs. The Competition

Neurogene Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Neurogene (NGNE) Competitors

NGNE vs. ZLAB, NRIX, BEAM, VRDN, and SLS

How does Neurogene compare to Zai Lab?

Does the media prefer ZLAB or NGNE?

Do analysts rate ZLAB or NGNE?

Which has better valuation & earnings, ZLAB or NGNE?

Which has more risk & volatility, ZLAB or NGNE?

Do insiders & institutionals have more ownership in ZLAB or NGNE?

Is ZLAB or NGNE more profitable?

Summary

How does Neurogene compare to Nurix Therapeutics?

Is NRIX or NGNE more profitable?

Which has higher earnings and valuation, NRIX or NGNE?

Which has more risk & volatility, NRIX or NGNE?

Do analysts prefer NRIX or NGNE?

Does the media refer more to NRIX or NGNE?

Do institutionals & insiders hold more shares of NRIX or NGNE?

Summary

How does Neurogene compare to Beam Therapeutics?

Is NGNE or BEAM more profitable?

Do analysts recommend NGNE or BEAM?

Which has stronger earnings & valuation, NGNE or BEAM?

Does the media favor NGNE or BEAM?

Do institutionals and insiders have more ownership in NGNE or BEAM?

Which has more risk & volatility, NGNE or BEAM?

Summary

How does Neurogene compare to Viridian Therapeutics?

Do institutionals & insiders hold more shares of NGNE or VRDN?

Do analysts recommend NGNE or VRDN?

Does the media favor NGNE or VRDN?

Is NGNE or VRDN more profitable?

Which has higher earnings & valuation, NGNE or VRDN?

Which has more risk and volatility, NGNE or VRDN?

Summary

How does Neurogene compare to SELLAS Life Sciences Group?

Which has more volatility and risk, SLS or NGNE?

Do insiders and institutionals hold more shares of SLS or NGNE?

Do analysts rate SLS or NGNE?

Does the media refer more to SLS or NGNE?

Is SLS or NGNE more profitable?

Which has higher valuation & earnings, SLS or NGNE?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

NGNE vs. The Competition

Neurogene Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools